Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

The purpose of this study is to test the safety & efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.

开始日期2023-07-01

申办/合作机构

Providence Health & Services

[+1]

NCT04365868

/ Terminated临床2/3期

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients with nonalcoholic steatohepatitis (NASH) cirrhosis and clinical signs of portal hypertension but without esophageal varices at baseline.

开始日期2020-06-25

申办/合作机构

Galectin Therapeutics, Inc.

NCT04332432

/ Completed临床1期

A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

This study will assess the pharmacokinetics of belapectin in subjects with mild, moderate, or severe hepatic impairment according to 3 different Child-Pugh categories: mild, moderate, or severe impairment, compared to matched healthy control subjects.

开始日期2020-06-16

申办/合作机构

Galectin Therapeutics, Inc.

100 项与 Belapectin 相关的临床结果

登录后查看更多信息

100 项与 Belapectin 相关的转化医学

登录后查看更多信息

100 项与 Belapectin 相关的专利（医药）

登录后查看更多信息

项与 Belapectin 相关的文献（医药）

2025-11-01·BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation

Review

作者: Zhang, Si ; Huang, Xiangyu ; Li, Jiale ; Chen, She

Despite advances in PD-1/PD-L1 combination therapies, clinical benefits remain limited and toxicity is significant. Galectins, a family of β-galactoside-binding lectins, have emerged as mechanistically distinct, multimodal targets with the potential to address these limitations. By modulating glycan-protein networks in the tumor microenvironment, galectin inhibition alleviates T cell exclusion, immune exhaustion, immunosuppressive cell activation, and steric blockade of PD-(L)1 antibodies. Several galectin inhibitors (e.g., GR-MD-02, GB1211, LYT-200) are under clinical evaluation. Early trials showing encouraging efficacy-toxicity profiles and some combinations received FDA Fast Track designations. This review summarizes mechanistic and clinical advances and highlights their translational implications for galectin-targeted combination therapies.

2024-07-31·Journal of Clinical and Translational Hepatology

Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease

Review

作者: Hu, Ye ; Fan, Jian-Gao ; Liu, Yu-Dong ; Sun, Chao ; Chen, Ying

Given the global prevalence and rising incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), the absence of licensed medications is striking. A deeper understanding of the heterogeneous nature of MASLD has recently contributed to the discovery of novel groups of agents and the potential repurposing of currently available medications. MASLD therapies center on four major pathways. Considering the close relationship between MASLD and type 2 diabetes, the first approach involves antidiabetic medications, including incretins, thiazolidinedione insulin sensitizers, and sodium-glucose cotransporter 2 inhibitors. The second approach targets hepatic lipid accumulation and the resultant metabolic stress. Agents in this group include peroxisome proliferator-activated receptor agonists (e.g., pioglitazone, elafibranor, saroglitazar), bile acid-farnesoid X receptor axis regulators (obeticholic acid), de novo lipogenesis inhibitors (aramchol, NDI-010976), and fibroblast growth factor 21/19 analogs. The third approach focuses on targeting oxidative stress, inflammation, and fibrosis. Agents in this group include antioxidants (vitamin E), tumor necrosis factor α pathway regulators (emricasan, pentoxifylline, ZSP1601), and immune modulators (cenicriviroc, belapectin). The final group targets the gut (IMM-124e, solithromycin). Combination therapies targeting different pathogenetic pathways may provide an alternative to MASLD treatment with higher efficacy and fewer side effects. This review aimed to provide an update on these medications.

2023-02-01·Alimentary pharmacology & therapeutics

Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis

Article

作者: Shlevin, Harold ; Harrison, Stephen A. ; Boudes, Pol ; Ren, Yayun ; Chalasani, Naga P. ; Tai, Dean ; Garcia‐Tsao, Guadalupe ; Chng, Elaine L. K. ; Goodman, Zachary ; Noureddin, Mazen

Summary:

Background and Aims:

In cirrhotic nonalcoholic steatohepatitis (NASH) clinical trials, primary efficacy endpoints have been hepatic venous pressure gradient (HVPG), liver histology and clinical liver outcomes. Important histologic features, such as septa thickness, nodules features and fibrosis area have not been included in the histologic assessment and may have important clinical relevance. We assessed these features with a machine learning (ML) model.

Methods:

NASH patients with compensated cirrhosis and HVPG ≥6 mm Hg (n = 143) from the Belapectin phase 2b trial were studied. Liver biopsies, HVPG measurements and upper endoscopies were performed at baseline and at end of treatment (EOT). A second harmonic generation/two‐photon excitation fluorescence provided an automated quantitative assessment of septa, nodules and fibrosis (SNOF). We created ML scores and tested their association with HVPG, clinically significant HVPG (≥10 mm Hg) and the presence of varices (SNOF‐V).

Results:

We derived 448 histologic variables (243 related to septa, 21 related to nodules and 184 related to fibrosis). The SNOF score (≥11.78) reliably distinguished CSPH at baseline and in the validation cohort (baseline + EOT) [AUC = 0.85 and 0.74, respectively]. The SNOF‐V score (≥0.57) distinguished the presence of varices at baseline and in the same validation cohort [AUC = 0.86 and 0.73, respectively]. Finally, the SNOF‐C score differentiated those who had >20% change in HVPG against those who did not, with an AUROC of 0.89.

Conclusion:

The ML algorithm accurately predicted HVPG, CSPH, the development of varices and HVPG changes in patients with NASH cirrhosis. The use of ML histology model in NASH cirrhosis trials may improve the assessment of key outcome changes.

项与 Belapectin 相关的新闻（医药）

2025-12-22

·BioSpace

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company’s previously submitted Type C meeting request regarding the development program for belapectin, its investigational galectin-3 inhibitor. The FDA converted the Company’s initial request for an in-person or teleconference meeting to a written response. Based on FDA’s written feedback, the Company believes there is alignment with the Agency on the patient population proposed for enrollment in a registration trial. In addition, Galectin Therapeutics had previously reached an agreement with the FDA on the use of a centralized, blinded endoscopy review for esophageal variceal assessment and plans to apply a similar approach for variceal evaluation in its next study. Pursuant to the written response from FDA, Galectin Therapeutics will pursue a follow-up Type C meeting to finalize remaining components of the next clinical trial design that were not fully resolved in the written response. This follow-up meeting will also provide an opportunity to present recently generated biomarker data, including findings highlighted at last month’s American Association for the Study of Liver Diseases (AASLD) meeting, which could not be incorporated in the original submission due to our stated objective of obtaining FDA feedback before the end of 2025. The Company views this next FDA interaction as an important step toward ensuring full clarity as it advances belapectin towards subsequent clinical development in a pivotal Phase 3 clinical trial. Galectin Therapeutics is also encouraged that the planned meeting will allow participation from prominent key opinion leaders, whose insights could not be integrated into the prior written-only exchange. Galectin Therapeutics remains committed to advancing belapectin’s development for patients with advanced fibrotic liver disease and continues to engage constructively with the FDA as it progresses the program. Dr. Khurram Jamil, Chief Medical Officer at Galectin Therapeutics, stated, “We appreciate the FDA’s written feedback and are encouraged by the agency’s evolving consideration of non-invasive tools and surrogate markers into clinical development for MASH cirrhosis. We look forward to discussing our updated data set within that regulatory context and further refining the clinical development strategy for belapectin.” Separately, the Company has entered into a new $10 million unsecured, convertible line of credit financing agreement provided by its chairman, Richard E. Uihlein. In connection with this agreement, the maturity dates of all of the Company’s convertible lines of credit and convertible notes payable to its chairman have been extended through June 30, 2027. The Company now believes that its cash resources, together with availability under these credit facilities, are sufficient to fund currently expected expenditures through at least March 2027. Joel Lewis, Chief Executive Officer at Galectin Therapeutics, added, “Our focus remains on advancing belapectin for patients with MASH cirrhosis and portal hypertension. We were pleased to receive feedback prior to year-end and look forward to continued dialogue as we work to finalize the next stage of clinical development. The strength of the data generated to date reinforces our confidence in belapectin’s potential, and we look forward to advancing this program with continued momentum. Finally, I would like to express our gratitude to Mr. Uihlein for once again increasing his commitment to the Company through the newest $10 million line of credit. This additional financing will enable us to continue to explore multiple strategies for the advancement of belapectin. We will provide updates as they become available.” About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on the Company’s cash resources and finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect”, “look forward”, “believe”, “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not produce positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Company Contact: Jack Callicutt, Chief Financial Officer (678) 620-3186 ir@galectintherapeutics.com Investors Relations Contacts: Kevin Gardner kgardner@lifesciadvisors.com Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.

快速通道临床3期

2025-10-21

·糖链密码

Nature子刊 | 糖基化RNA：癌症免疫治疗的新钥匙？

文献精读 | 癌症中的异常糖基化：分子功能与治疗潜力版权声明：本文是基于已发表学术文献《Altered glycosylation in cancer: molecular functions and therapeutic potential》的解读与整理，旨在进行知识分享。版权归原作者所有，本文禁止用于任何商业用途。原文信息：标题：Altered glycosylation in cancer: molecular functions and therapeutic potential 期刊：Cancer Communications | 影响因子：24.9 (2024 JCR)🎯 核心摘要关键要点 🧬 糖基化是关键的蛋白质翻译后修饰，调控蛋白折叠、运输和定位 🦠 糖基化模式改变是癌症的显著特征，与多种恶性进程相关 🔬 新发现：糖基化RNA (glycoRNA) 作为新的糖基化底物 🎯 临床应用：作为诊断生物标志物和治疗靶点关键词: 糖基化免疫细胞衰老肿瘤生物标志物癌症治疗🧬 糖基化类型与功能解析糖基化基础概念糖基化是糖链在酶催化下连接到蛋白质或脂质上的过程，主要发生在线粒体和Golgi体中类型连接位点核心功能癌症相关N-糖基化天冬酰胺(Asn)氮原子蛋白质折叠、内质网稳态、自噬最普遍，研究最深入O-糖基化丝氨酸/苏氨酸(Ser/Thr)氧原子蛋白质稳定、信号转导、免疫识别包括O-GlcNAc和黏蛋白型C-糖基化色氨酸(Trp) 蛋白质折叠、分泌、稳定性相对罕见，如PDGF-CGPI锚定蛋白质C末端膜锚定、信号转导、细胞粘附 CD48等免疫相关蛋白GlycoRNA RNA分子新发现：膜定位，Siglec受体互作，免疫调节前沿研究领域🔬 糖基化在癌症中的核心作用🧫 肿瘤转移机制关键分子与通路 B3GNT5: N-糖基化促进稳定，增强基底样乳腺癌干细胞特性和侵袭性 GALNT6: O-糖基化GRP78，激活MEK/ERK通路 → 促进肺腺癌EMT、迁移和侵袭 FUT2:诱导LRP1岩藻糖基化 → 抑制结直肠癌EMT和转移 SLC35A2：通过调节糖基化增强细胞粘附能力，促进肝癌转移。 ST6GAL1: 驱动N-聚糖α2,6唾液酸化 → 促进前列腺癌生长和侵袭 🛡️ 免疫逃逸机制免疫逃逸通路 ST3GAL1: CD55唾液酸化 → 乳腺癌免疫逃逸 FUT8: B7H3异常糖基化 → 抑制三阴性乳腺癌免疫反应 GALNT7：改变前列腺癌中的O-糖基化，加速癌症发展并与免疫信号通路相关。PD-L1糖基化多层次调控 O-GlcNAc修饰抑制其溶酶体降解。 TMUB1通过招募STT3A增强其N-糖基化和稳定性。 B4GALT1介导其N-连接糖基化，阻止其转录后降解。 TGF-β1通过c-Jun/STT3A通路介导其糖基化。 ⚡️ 代谢重编程代谢通路调控网络 O-GlcNAc修饰：作为营养传感器，整合糖、蛋白质、脂肪和核酸代谢。 PGK1：糖基化上调其代谢酶活性并诱导线粒体转位，加剧Warburg效应。 PIGT：通过调节GLUT1的糖基化和膜转位增强膀胱癌细胞的糖酵解。 MDH1： O-GlcNAc修饰增强其活性，促进胰腺癌的谷氨酰胺代谢。 SCAP： N-糖基化激活SREBP1，调节肿瘤脂质代谢。 ⚒️ 铁死亡调控铁死亡相关通路 O-GlcNAc修饰: 动态调控铁蛋白自噬和线粒体自噬 SLC3A2 (4F2hc): N-糖基化维持系统Xc-活性 → 胰腺癌铁死亡敏感性 USP8-OGT-SLC7A11: O-GlcNAc修饰轴 → 抑制肝癌铁死亡 ZEB1 O-GlcNAc修饰: 激活脂质生成基因 → 脂质过氧化依赖性铁死亡 ⏳ 细胞衰老衰老调控机制 NGI-1: 抑制OST → 阻断EGFR膜定位 → 诱导RTK肿瘤细胞衰老 O-GlcNAc修饰: KRAS突变肺癌中升高 → 抑制致癌基因诱导衰老(OIS) → 加速肿瘤发生 🩺 临床转化与应用📊 糖基化肿瘤生物标志物临床应用分类类别代表性标志物临床应用价值糖蛋白标志物 AFP, CEA, PSA, CA19-9, CA125, HER2 多种癌症诊断、预后与疗效监测的经典标志物糖基转移酶标志物 GALNT6, POFUT1, GCNT2, B4GALNT2 新型预后预测因子和潜在治疗靶点🚀 前沿发现糖基化的外泌体PD-L1相比总PD-L1具有更高的诊断准确性和免疫疗效预测价值💊 靶向治疗策略临床试验进展药物/疗法作用机制适应症研发阶段GMI-1271 E-选择素抑制剂急性髓系白血病 I/II/III期GR-MD-02 半乳糖凝集素抑制剂黑色素瘤、NSCLC等 I期MUC1 CAR-T 靶向异常糖基化MUC1 肝内胆管癌 I/II期2-fluorofucose 岩藻糖基化抑制剂晚期实体瘤 I/II期治疗突破方向 🔄 克服耐药: 糖基化抑制剂（如衣霉素）可逆转胃癌化疗耐药 🛡️ 增强免疫: 干扰肿瘤N-糖基化 → 显著提升CAR-T细胞对实体瘤疗效 💉 癌症疫苗: MUC1糖肽疫苗等显示出良好前景💎 结论与展望🎯 核心结论异常糖基化在癌症发生发展中扮演中心角色，是极具潜力的诊断生物标志物库和治疗靶点资源⚠️ 当前挑战结构复杂性: 糖链结构的多样性和肿瘤异质性转化困难: 临床转化面临挑战，现有标志物缺乏糖型信息和肿瘤特异性技术限制: 糖基化研究技术平台仍需完善🔭 未来方向精准医学: 开发糖型明确的精准生物标志物靶向治疗: 利用小分子或酶抑制剂靶向肿瘤特异性糖基化通路多组学整合: 结合糖组学、蛋白质组学与基因组学，深入解析调控网络药物研发: 推动糖基化靶向药物（酶抑制剂、聚糖拮抗剂）的研发与应用版权归属：本文内容是基于学术文献《Altered glycosylation in cancer: molecular functions and therapeutic potential》的解读与整理，原文献版权归作者及出版商John Wiley & Sons Ltd.所有。 — END — 声明：本公众号推送文章仅为学术交流使用，不主张原文版权归属。如涉侵权，请及时联系我们，我们将立即删除相关内容。若文献解读或作者简历存在疏漏，谨向作者团队深表歉意。请通过公众号后台私信告知，我们将在第一时间核实并修改重发。衷心感谢您的理解与支持。

2025-06-18

·PRNewswire

Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs, and their lack of life-extension successes. That said, with the recent close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers remain optimistic. For investors to note, oncology innovators have provided recent developments to pay attention to, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Galectin Therapeutics, Inc. (NASDAQ: GALT), ProPhase Labs, Inc. (NASDAQ: PRPH), CG Oncology, Inc. (NASDAQ: CGON), and Perspective Therapeutics, Inc. (NYSE-American: CATX). Continue Reading Pelareorep Facts (PRNewsfoto/USA News Group) With reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. According to analysts at ResearchAndMarkets, the global oncology market is projected to reach US$866.1 billion by 2034, rising at a 10.8% CAGR, while Vision Research Reports projects the global oncology market to surpass US$903.81 billion by 2034, at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) just announced a major leadership transition that could mark a pivotal chapter in its clinical and corporate trajectory. The company has appointed Jared Kelly as Chief Executive Officer and member of the Board, a move that brings in a seasoned biotech dealmaker known for high-value M&A and immuno-oncology strategy. Kelly most recently played a central role (as General Counsel) in the $2 billion sale of Ambrx Biopharma to Johnson & Johnson. Prior to that, he advised numerous biotech firms on licensing and acquisitions during his tenure at leading law firms Kirkland & Ellis LLP and Lowenstein Sandler LLP. In joining Oncolytics, he inherits one of the most intriguing immunotherapy agents and pipelines in clinical oncology: pelareorep, a virus-based agent with broad synergy potential in solid and hematologic tumors. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear priority: advancing pelareorep toward late-stage inflection points with a capital-efficient and partnership-aware strategy. The asset currently holds FDA Fast Track designation in both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC)—a rare distinction that reinforces its regulatory momentum. In trials to date, pelareorep has consistently demonstrated immune activation, synergy with chemotherapies and checkpoint inhibitors, and unusually strong response rates across difficult-to-treat cancers. In metastatic pancreatic cancer (mPDAC), pelareorep has delivered over 60% objective response rates in tumor evaluable patients across Phase 1 and 2 studies—more than double those observed in historical controls— and, separately, two-year survival rates 4-6 times those observed in control patients or in prior studies. In HR+/HER2- metastatic breast cancer, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed meaningful survival benefit. And in anal cancer, early data from a phase 2 cohort combining pelareorep with a checkpoint inhibitor showed partial or complete responses in nearly half of evaluable patients—far exceeding historical norms for monotherapy. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." To align incentives with long-term shareholder value, Kelly's compensation package includes equity and milestone-based awards tied to future strategic transactions and financings. The structure reflects Oncolytics' intention to drive both clinical and corporate progress without overextending its cap table—while remaining attractive to potential collaborators. As multiple programs advance within the GOBLET study—including pancreatic and anal cancer cohorts backed by regulatory support and third-party funding— Oncolytics appears poised to benefit from a combination of scientific traction, capital flexibility, and strategic leadership. Photo - CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Galectin Therapeutics, Inc. (NASDAQ: GALT) is advancing belapectin, a galectin-3 inhibitor with applications in both MASH cirrhosis and oncology, including combination immunotherapy for head and neck cancers. The company recently presented updated data at the 2025 EASL Congress highlighting statistically significant improvements in liver stiffness and reduced varices progression. "This quarter, we remained laser-focused on advancing additional analyses for belapectin," said Joel Lewis, CEO and President of Galectin Therapeutics. "We look forward to sharing more biomarker data as it becomes available." With Fast Track Designation in place, Galectin continues to evaluate expansion into cancer indications pending a development partner. ProPhase Labs, Inc. (NASDAQ: PRPH) has recently reported successful validation of its BE-Smart™ molecular test in detecting esophageal cancer using brush cytology samples, showing a technical success rate above 95%. "The ability to run BE-Smart on brush biopsy samples opens the door to much broader clinical use," said Ted Karkus, CEO of ProPhase Labs. "BE-Smart now stands apart as the only advanced molecular test designed to work with both forceps biopsies and brush-based tissue collection." The company is positioning BE-Smart for near-term commercialization, targeting the $10 billion esophageal disease testing market. With dual compatibility across standard biopsy methods, BE-Smart is designed to improve early detection and risk stratification for deadly cancers like EAC. CG Oncology, Inc. (NASDAQ: CGON) continues to progress its lead candidate cretostimogene, an oncolytic immunotherapy aimed at non-muscle invasive bladder cancer (NMIBC). "With best-in-disease durability and tolerability data from the BOND-003 Cohort C registrational trial recently presented at AUA, we are well positioned to initiate our BLA submission in the second half of the year for the treatment of patients with HR NMIBC unresponsive to BCG," said Arthur Kuan, Chairman and CEO of CG Oncology. "If approved, I'm confident that cretostimogene is well positioned to become backbone therapy in NMIBC, potentially addressing more than 70% of the market opportunity in need of a new and innovative therapy." At the 2025 AUA Annual Meeting, the company reported a 42.3% complete response at 24 months in its BOND-003 Cohort C, with nearly all patients avoiding progression to invasive disease. CG plans to initiate its BLA submission in the second half of 2025 while advancing multiple cohorts across BCG-unresponsive and intermediate-risk populations. Backed by over $688 million in cash and marketable securities, CG Oncology is positioned to reach multiple late-stage milestones over the next 12 months. Perspective Therapeutics, Inc. (NYSE-American: CATX) announced updated Phase 1/2a trial results for [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting, with promising signs of durability and safety in patients with progressive SSTR2-positive neuroendocrine tumors. "[212Pb]VMT-α-NET is emerging as an exciting potential treatment option for patients with progressive NETs, with continued durability of anti-tumor activity at the dose level used in Cohort 2 and a favorable tolerability profile seen so far," said Vikas Prasad, MD, Associate Professor of Radiology at the Mallinckrodt Institute of Radiology, Siteman Cancer Center. "I am eager to find more treatments to help my patients fight hard against their disease and return to their normal lives." Among nine early patients in Cohorts 1 and 2, seven remained progression-free after a year, with multiple confirmed objective responses now observed. Safety data from 42 total treated patients showed no dose-limiting toxicities, no Grade 4/5 adverse events, and no treatment-related discontinuations. The company is now in discussions with the FDA to finalize dose selection and continue advancement of this alpha-emitting radiotherapeutic platform. Source: CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo - SOURCE USA News Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果ASCO会议免疫疗法高管变更快速通道

100 项与 Belapectin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11495	-	-	DB15125

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
食管胃静脉曲张	临床3期	美国	Galectin Therapeutics, Inc.	2020-06-25
食管胃静脉曲张	临床3期	阿根廷	Galectin Therapeutics, Inc.	2020-06-25
食管胃静脉曲张	临床3期	澳大利亚	Galectin Therapeutics, Inc.	2020-06-25
食管胃静脉曲张	临床3期	比利时	Galectin Therapeutics, Inc.	2020-06-25
食管胃静脉曲张	临床3期	加拿大	Galectin Therapeutics, Inc.	2020-06-25
食管胃静脉曲张	临床3期	智利	Galectin Therapeutics, Inc.	2020-06-25
食管胃静脉曲张	临床3期	法国	Galectin Therapeutics, Inc.	2020-06-25
食管胃静脉曲张	临床3期	德国	Galectin Therapeutics, Inc.	2020-06-25
食管胃静脉曲张	临床3期	以色列	Galectin Therapeutics, Inc.	2020-06-25
食管胃静脉曲张	临床3期	墨西哥	Galectin Therapeutics, Inc.	2020-06-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04365868 (NAVIGATE, Company_Website) 人工标引	临床2/3期	代谢功能障碍相关脂肪性肝炎	355	BelapectinBelapectin 2mg/kg/LBM	淵鬱壓鹹鑰築鹽艱糧淵(製遞選膚鏇繭鬱壓夢蓋) = 願蓋選膚選鑰壓襯蓋範廠鬱襯範襯積網糧鑰憲 (製積衊壓醖築夢繭獵糧 ) 未达到更多	不佳	2024-12-20
				belapectin 4 mg/kg/LBMbelapectin 4 mg/kg/LBM	-
NCT02575404 (Biospace) 人工标引	临床1期	转移性黑色素瘤 \| 头颈部肿瘤	14	Belapectin+KEYTRUDA (Melanoma)	蓋構憲膚獵廠鹹顧衊齋(積鬱遞獵衊構構鏇衊遞) = The most frequent adverse event related to pembrolizumab, in six patients, was grade 1 (mild) pruritus (itching), a known and labeled side-effect of pembrolizumab 夢簾構網鏇廠製衊遞獵 (廠顧夢艱構簾鏇繭構膚 ) 更多	积极	2021-07-09
				Belapectin+KEYTRUDA (HNSCC)
NCT02462967 (NASH-CX, CTgov)	临床2期	肝纤维化 \| 代谢功能障碍相关脂肪性肝炎 \| 门静脉高血压	162	GR-MD-02 (2 mg/kg GR MD 02)	窪糧醖遞遞蓋醖醖範廠(鹹網觸鬱積積糧範壓遞) = 廠衊簾壓艱襯窪選顧繭窪鹹鬱鹽積築鏇簾憲壓 (鹽積築鏇鏇淵顧糧夢鬱, 4.018) 更多	-	2020-10-08
				GR-MD-02 (8 mg/kg GR MD 02)	窪糧醖遞遞蓋醖醖範廠(鹹網觸鬱積積糧範壓遞) = 艱壓齋窪簾願衊築襯製窪鹹鬱鹽積築鏇簾憲壓 (鹽積築鏇鏇淵顧糧夢鬱, 3.100) 更多
NCT02421094 (NASH-FX, CTgov)	临床2期	肝纤维化 \| 代谢功能障碍相关脂肪性肝炎	30	Placebo	觸淵糧艱餘築壓壓蓋網(膚淵齋網網積夢願餘鹹) = 築窪遞網淵構醖壓獵鑰襯醖構範鑰鏇簾積鏇淵 (衊艱蓋夢廠淵鏇選艱鏇, 鹽範糧鹹遞艱衊製齋蓋 ~ 糧製壓積壓餘獵餘範顧) 更多	-	2020-09-28
NCT02407041 (CTgov)	临床2期	斑块状银屑病	5	GR-MD-02	鑰鬱餘鹹遞積簾簾餘鏇 = 獵選齋壓鬱築壓鏇壓鬱簾選鏇襯壓壓糧鑰壓選 (積壓憲餘顧憲積繭艱構, 築鏇繭願廠餘襯願積壓 ~ 獵築糧醖廠窪築顧鬱齋) 更多	-	2020-09-07
NCT02462967 (Pubmed \| Gastroenterology)	临床2期	代谢功能障碍相关脂肪性肝炎 \| 纤维化 \| 门静脉高血压	162	Belapectin 2 mg/kg	選簾壓遞遞蓋網糧夢醖(壓觸鹹蓋網製夢鹹簾齋) = 網糧壓衊繭願糧製鏇夢鬱遞鑰簾膚鹽積齋鹹簾 (憲淵觸壓夢鏇餘觸糧範 )	-	2020-04-01
				Belapectin 8 mg/kg	選簾壓遞遞蓋網糧夢醖(壓觸鹹蓋網製夢鹹簾齋) = 鹽遞遞簾簾遞鑰繭壓醖鬱遞鑰簾膚鹽積齋鹹簾 (憲淵觸壓夢鏇餘觸糧範 )
NCT02117362 (PipelineReview) 人工标引	临床1期	黑色素瘤	-	Pembrolizumab+GR-MD-02	衊築構廠窪觸遞顧餘簾(膚憲繭醖窪襯鏇鏇網簾) = 鬱糧膚遞餘簾鹽醖夢蓋夢廠衊遞淵網夢獵顧鹽 (鬱膚壓壓壓觸襯衊廠壓 )	积极	2017-11-13